Virtu Financial LLC Bluebird Bio, Inc. Transaction History

Virtu Financial LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$0.85 - $1.26 $236,105 - $349,991	277,771 New	277,771 $273,000
Q4 2023 Feb 26, 2024	BUY	$1.32 - $4.83 $302,995 - $1.11 Million	229,542 New	229,542 $317,000
Q2 2022 Aug 09, 2022	BUY	$2.94 - $5.23 $206,740 - $367,773	70,320 New	70,320 $291,000
Q3 2021 Nov 12, 2021	SELL	$11.24 - $21.0 $107,589 - $201,012	-9,572 Closed	0 $0
Q2 2021 Sep 17, 2021	BUY	$18.04 - $22.09 $172,678 - $211,445	9,572 New	9,572 $306,000
Q1 2021 May 19, 2021	SELL	$16.59 - $33.89 $341,737 - $698,100	-20,599 Closed	0 $0
Q4 2020 Feb 24, 2021	BUY	$27.5 - $37.92 $566,472 - $781,114	20,599 New	20,599 $891,000
Q4 2019 Feb 04, 2020	SELL	$46.96 - $61.67 $247,150 - $324,569	-5,263 Closed	0 $0
Q3 2019 Nov 20, 2019	BUY	$59.47 - $93.1 $192,088 - $300,713	3,230 Added 158.88%	5,263 $483,000
Q2 2019 Aug 13, 2019	SELL	$75.84 - $105.21 $12,361 - $17,149	-163 Reduced 7.42%	2,033 $259,000
Q1 2019 Apr 12, 2019	SELL	$64.44 - $104.11 $69,401 - $112,126	-1,077 Reduced 32.91%	2,196 $345,000
Q4 2018 Jan 16, 2019	BUY	$59.1 - $93.26 $193,434 - $305,239	3,273 New	3,273 $325,000
Q2 2018 Jul 30, 2018	SELL	$99.64 - $127.59 $385,806 - $494,028	-3,872 Closed	0 $0
Q2 2018 Jul 30, 2018	BUY	$99.64 - $127.59 $111,497 - $142,773	1,119 Added 40.65%	3,872 $608,000
Q1 2018 May 14, 2018	BUY	$105.8 - $150.94 $58,719 - $83,771	555 Added 25.25%	2,753 $470,000
Q4 2017 Feb 09, 2018	SELL	$81.25 - $130.7 $612,950 - $986,000	-7,544 Reduced 77.44%	2,198 $391,000
Q3 2017 Nov 20, 2017	BUY	$57.74 - $91.42 $562,503 - $890,613	9,742	9,742 $1.34 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.